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Posttranslational modiﬁcations (PTMs) modulate protein function in most eukaryotes and have a ubiquitous role in diverse
range of cellular functions. Identiﬁcation, characterization, and mapping of these modiﬁcations to speciﬁc amino acid residues
on proteins are critical towards understanding their functional signiﬁcance in a biological context. The interpretation of proteome
data obtained from the high-throughput methods cannot be deciphered unambiguously without a priori knowledge of protein
modiﬁcations. An in-depth understanding of protein PTMs is important not only for gaining a perception of a wide array of
cellular functions but also towards developing drug therapies for many life-threatening diseases like cancer and neurodegenerative
disorders. Many of the protein modiﬁcations like ubiquitination play a decisive role in various drug response(s) and eventually
in disease prognosis. Thus, many commonly observed PTMs are routinely tracked as disease markers while many others are used
as molecular targets for developing target-speciﬁc therapies. In this paper, we summarize some of the major, well-studied protein
alterations and highlight their importance in various chronic diseases and normal development. In addition, other promising
minor modiﬁcations such as SUMOylation, observed to impact cellular dynamics as well as disease pathology, are mentioned
brieﬂy.
1.Introduction
With current advances in the ﬁelds of systems biology and
proteomics,theinterestindecipheringproteinmodiﬁcations
and their impact on the cellular microenvironment and dis-
ease pathophysiology is greatly enhanced. Proteins are large
macromolecules comprised of a speciﬁc sequence of amino
acids. Although protein folding and refolding play a critical
role in protein function, the modiﬁcation of amino acids and
their side chains contributes signiﬁcantly to the structural
and functional diversity of the proteins. These modiﬁcations
impartcomplexitytotheeukaryoticproteomesthatisseveral
orders of magnitude greater than the coding capacity of the
genome. The common modiﬁcations include phosphoryla-
tion, acetylation, glycosylation, ubiquitination, acetylation,
and hydroxylation. Posttranslational modiﬁcations (PTMs)
of proteins inﬂuence the enzyme activity, protein turnover
and localization, protein-protein interactions, modulation
for various signaling cascades, DNA repair, and cell division.
Given the pivotal role of PTMs in the regulation of
cellular environment, there is a constant eﬀort to develop
novel, highly sensitive, and sophisticated PTM identiﬁcation
techniques. Some of these techniques are targeted towards
identifying speciﬁc PTMs like the modiﬁcation of the
histone tails recognized by specially designed probes while
other techniques are more robust like surface-enhanced
Raman spectroscopy and mass spectrometry [1–3]. A novel
technology called “multidimensional protein identiﬁcation
technology or MudPIT,” which is a combinatorial method
chromatography in conjunction with mass spectrometry,2 Journal of Amino Acids
has been eﬃcient in discovering global PTM [4]. Tradi-
tional biochemical methods like Western blotting and SDS-
PAGE are widely used to conﬁrm the high-throughput
results obtained from the spectroscopic methods as well
as for understanding the biological signiﬁcance of PTMs
in vivo. In addition, there have been successful attempts
in developing in silico algorithms that can reliably predict
various PTMs in a given protein sample. Other artiﬁcial
PTMs like biotinylation, which attach a prosthetic group
to a protein, are frequently used to understand protein-
protein interaction(s) that results from the changes in
three-dimensional structure of protein. Although more than
150 protein modiﬁcations have been reported, a detailed
assessment of each modiﬁcation is beyond the scope of this
paper. We have focused on major modiﬁcations, which have
received signiﬁcant attention by the research community in
the past few decades.
2.Acetylation
One of the most common protein modiﬁcations is the
acetylation of lysine residue. The acetylation of proteins is
mainly a cotranslational and posttranslational process. The
histone acetylation as well as deacetylation is of particular
interest due to its role in gene regulation [5, 6]. This occurs
on the lysine residue of histone proteins at the N-terminal
tail of lysine and is facilitated by the enzymes, histone
acetylases (HATs), or histone deacetylases (HDACs). A single
lysine alteration on histones signiﬁcantly impacts the cellular
homeostasis since the acetylation status of histones regulates
various transcription factors, molecular chaperones, and
cellular metabolism [7, 8]. In addition, regulation of histone
acetylation by the HATs and HDACs has a well-established
link to aging and various neurological and cardiovascular
diseases [9–12]. Finally, at least one HDAC family, MYST
proteins, is shown to participate in a diverse array of
functions in health and disease to modulate the fate of stem
cells and chromatin state [13].
In prokaryotes, the acetylation of glutamic acid and
aspartic acid has also been observed. The conversion of
glutamic acid to N-acetylglutamic acid is an important
intermediate step for ornithine synthesis in bacteria [14].
Recent studies not only have linked the process of
protein acetylation with a number of diseases but also have
shown that amino acid acetylation signiﬁcantly contributes
to the overall pathophysiology of the diseases [9–12]. One
such study has noted that the increased acetylation of
the cytoskeletal proteins, especially microtubule proteins,
in response to the reactive oxygen species (ROS) and
thus suppression of SIRT2 aggravates the mitochondrial
dysfunction in the CPEO (chronic progressive external
ophthalmoplegia) syndrome patients [15]. Conversely, the
study showed that the lysine hyperacetylation of the OGG1
enzyme, an important DNA repair enzyme, in response
to the ROS, is a required step for the activation of the
DNA repair system [16]. Similarly, another member of
the deacetylases family, SIRT1, has been shown to be
downregulated in oxidative stress-induced endothelial cells.
However, pretreatment with a pharmacological agent like
resveratrol was shown to attenuate the SIRT1 levels as well
as eNOS acetylation. Thus, identiﬁcation of the eNOS as a
substrate for SIRT1 in the endothelial cells has been a pivotal
step in understanding the pathology and mechanism of the
cardiopulmonary diseases and vasculature [17].
Acetylation of proteins and carbohydrates has also been
evaluated as a target for cancer therapy [9, 18]. Chammas
et al. have reported the use of N-acetylation as well as O-
acetylation of the surface tumor antigens as a tool for ther-
apeutic development against diﬀerent types of melanomas
and leukemias [9].
A number of acetoproteins have been implicated in the
cognitive disorders like dementia and Alzheimer’s disease
[10]. In the case of dementia, lysine acetylation of tau
proteins results in “tau tangles” while in Alzheimer’s dis-
ease lysine hyperacetylation of β-amyloid peptide results
in impaired cognition [10]. Additionally, mouse models
have demonstrated that alterations in histone acetylation
pattern play a role in age-dependent memory impairment
[11]. Thus, these studies indicate that targeting lysine
acetylases and deacetylases might be promising avenue for
developing novel therapies for neurodegenerative diseases.
Thewidespreadanddynamicnatureoflysineacetylationand
the nexus that exists between epigenesis-directed transcrip-
tional regulation and metabolism has been comprehensively
reviewed [19].
3. Carbonylation
Protein carbonylation can result from excessive oxidative
stress in a biological system. It is an irreversible PTM which
may lead to the formation of nonfunctional proteins, in
turn leading to many diseases. Many disorders including
autoimmune diseases and cancer are mediated by increased
p r o d u c t i o no fr e a c t i v eo x y g e na sw e l la sn i t r o g e ns p e c i e s
(ROS and RNS) in the cell. However, the role of ROS
and RNS in protein oxidation is less understood. Protein
carbonylation has received signiﬁcant attention as an indi-
cator of oxidative or genotoxic stress [20, 21]. Investiga-
tion of the Murphy Roth’s Large (MRL) mouse model,
used widely in tissue regeneration studies, suggested that
common environmental contaminants like trichloroethene
(TCE) increased ROS and RNS leading to the production
of high amounts of nitrotyrosine and protein carbonyl(s), a
classic hallmark response to high oxidative stress [22]. These
byproducts are seen to induce a number of autoimmune
diseases like systemic sclerosis and fasciitis. Elevated levels of
protein carbonyls and nitrotyrosine have also been observed
in other instances with high oxidative stress, mitochon-
drial disorders, indicative of hypocitrullinemia and loss of
glutathione (iGSH) [23]. Thus, carbonylation of amino
acids like proline, arginine, lysine, threonine, glutamate, and
aspartate (see Table 1) is irreversible and results in a non-
functional protein, which then participates as a mediator in
a number of chronic diseases, especially the ones that are
inﬂuenced by the status of oxidative stress in a cell [24].
A recent proteomics study has detailed the identiﬁcation of
carbonylation pattern as a ﬁngerprint for oxidative stress
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therapy for many mitochondrial, neurological, and cardio-
vascular diseases. Another proteomics study conducted in
mouse model for an early stage of alcoholic liver disease
(ALD) identiﬁed biomarkers for early stage ALD wherein
a carbonylated protein expression pattern was highlighted
[26].
At least one study that focused on sepsis in mouse
models concluded that N-acetylcysteine, an antioxidant,
induces cellular antioxidant defense and prevents nitration
of tyrosine residues and protein carbonylation. These results
indicate the therapeutic potential of N-acetylcysteine for
treating sepsis patients [27]. Protein carbonylation, partic-
ularly of UCH-L1 forming carbonyl-modiﬁed UCH-L1 and
its interaction with other proteins like tubulin, was thought
to be one of the causes of familial as well as sporadic
Parkinson’s disease (PD) [28]. The carbonyl-modiﬁed UCH-
L1 is proposed to be an investigative tool to explore the
underlying molecular mechanism of PD development [28].
This carbonyl modiﬁcation may be of therapeutic value
targeting the familial and/or sporadic PD [28]. Choi et al.
demonstrated the irreversible carbonylation of protein to
methioninesulfoneasanindicatorofoxidativestressdamage
in cases of the sporadic PD and Alzheimer’s as well as other
neurodegenerative diseases [29]. In recent years, proteomic
tools and methods for the identiﬁcation of sites of protein
carbonylation have been widely developed [30].
4. GlycosylationandGlycation
Another well-studied cotranslational and posttranslational
mechanism is the addition of a sugar moiety to proteins,
lipids, or other organic molecules inside or outside of the
cell. Glycosylation being an enzyme-directed reaction is site
as well as substrate speciﬁc, tightly regulated and reversible.
On the other hand, glycation is a random event that most
often leads to the formation of defective or non-functional
biomolecules.
Glycans resulting from glycosylation are classiﬁed under
one of ﬁve known classes: N-linked glycans, O-linked
glycans, C-linked glycans, phosphoglycans, and glypiation
(GPI-anchored). O-linked glycans have been shown to
participate in the diverse cellular processes and development
[31, 32]. Glycosylation, a covalent modiﬁcation, plays a
central role in protein localization, protein-protein interac-
tions, structural stability of the cell, immune responses, and
modulatingofcellsignaling[32,33].Thus,anydysfunctional
glycans formed in the cell could lead to diseases including
cancer, liver cirrhosis, diabetes, and exacerbated HIV infec-
tion[34,35].Anovelglycosylationpredictiontooldeveloped
by Szab´ a et al. utilizes currently available databases of the T-
cell antigens and autoantigens glycosylation [36].
O-glycosylation, as well as phosphorylation, has been
shown to have a beneﬁcial eﬀect in Alzheimer’s disease by
reducing the formation of neuroﬁbrillary tangles in neurons
[37]. Glycosylation of prion (PrP), a cell surface protein
and a transmissible agent, is a determinant of the ﬁnal
disease outcome in the host [38]. Recent characterization
of glycosylation sites on apolipoprotein E (apoE) revealed
a novel glycosylation site in addition to the already known
sites as well as at least 8 new complex glycans in secreted and
cellular apoE [39]. The involvement of apoE in Alzheimer’s
disease, atherosclerosis, and immune responses is well doc-
umented, and this novel information can help gain insight
towards understanding the mechanistic role of glycosylated
apoE residues in these diseases [39]. Improper or incomplete
glycosylation in the Fc receptor for immunoglobulin A has
been shown to impact the IgA-mediated immune response
which in turn aﬀects many diseases including HIV, alcoholic
liver cirrhosis, and other neuropathies [34, 40].
Other glycation products called (AGEs) have been
implicated in cardiovascular diseases, cataract, and diabetes
mellitusapart[41,42].Theendproductsarecommonlyused
asmarkerstoevaluatethediseaseprognosissinceinhibitinga
subclass of the AGEs has been shown to beneﬁt physiological
conditions like diabetes and arthrosclerosis [43–46]. Finally,
glycosylation is shown to be a contributing factor in cancer
cell transformation via Src(s) as well as in regulating various
signaling pathways like Wnt-β catenin pathway, thereby
aﬀecting the disease physiology and ﬁnal outcome [47].
5. Hydroxylation
Hydroxylation is an important detoxiﬁcation reaction in
the cell and is mostly facilitated by the group of enzymes
called hydroxylases. It is also one of the few reversible,
post-translational modiﬁcations and hence has a prominent
relevance to the cellular physiology.
Prolinehydroxylation-mediated modiﬁcation ofcollagen
has been studied extensively since it has signiﬁcant impli-
cations on the structural physiology of the cell [48]. Some
cancers or metabolic disorders like scurvy are linked to the
lack of proline hydroxylation due to ascorbate deﬁciencies,
an important component of the reaction [49]. The enzyme
prolyl 4-hydroxylase that catalyzes the conversion of 4-
hydroxyproline to collagen, is one of the most well-studied
enzymes in this group [50, 51].
Proline hydroxylation is an important step in activating
antioxidant defense against hypoxia via hypoxia inducible
factor (HIF) [52]. Under normoxia, proline hydroxylation
acts as a regulatory step for HIF1α and 2α to bind to
the von Hippel-Lindau tumor suppressor (pVHL) E3 ligase
complex, which targets both the factors for rapid deg-
radation by ubiquitin-proteasome complex [52]. Under
hypoxic conditions, however, the abrogation of proline hyd-
roxylation as well as asparagine hydroxylation is necessary
for the continual action of the HIF transcription factor.
Thus, hydroxylation of asparagine and proline acts as a
“hypoxic switch” for induction of HIF under the low
oxygen conditions [53]. Further, proline hydroxylation of
HIF similar to that under normoxic conditions was shown
to be protumorigenic [54, 55]. The inhibition of normoxic
HIF1αwassuggestedasatherapeuticalternativeinsuchcases
[55, 56]. A number of in silico prediction tools augment
the understanding of the complexity of the process as well
as designing novel therapies for diseases like cancer and
cholestatic liver disease [57].Journal of Amino Acids 5
Other amino acids that undergo hydroxylation include
phenylalanine, tyrosine, and tryptophan, all of which have
aromatic side chains [58]. Several genetic diseases are linked
to the lack of hydroxylation of aromatic amino acids like
that of phenylketonuria (PKU) and hyperphenylalaninemia,
due to a defect in phenylalanine hydroxylase, an enzyme that
converts phenylalanine to tyrosine [59]. Tyrosine hydroxy-
lase is used as a molecular target to treat hypertension [60–
62]. This enzyme is also known to act as an autoantigen
in autoimmune polyendocrine syndrome (APS) type I. On
the other hand, tryptophan hydroxylation, catalyzed by
tryptophan hydroxylase, is a critical regulatory step in the
production of an important neurotransmitter, serotonin
[63].
6. Methylation
Protein methylation has a tremendous impact in health
and disease, spanning from embryonic to postnatal devel-
opmental stages in numerous physiological conditions such
as cancer, lipofuscinosis, and occlusive disease [64–68].
The most commonly methylated amino acid residues are
lysine and arginine with lysine methylation receiving special
consideration due to its role in epigenetics and chromatin
remodeling [69].
Histone methyltransferases (HMTs), also sometimes
referredtoasthehistonelysinemethyltransferases(HKMTs),
speciﬁcally target lysine residues in histones, which regulate
gene expression [69]. Histone methylation together with the
histone acetylation also has been shown to control cellular
RNA synthesis including activation and inhibition of speciﬁc
RNAs types, metabolism, and degradation in vivo [69, 70].
In addition, there is a growing number of lysine methyl-
transferases that methylate nonhistone proteins on lysine
residue that are being constantly identiﬁed [69]. These
can methylate proteins like p53 (Figure 1), ERα,N F - κB,
and pCAF and other transcription factors that have been
implicated in tumorigenesis and other metabolic disorders
like inﬂammatory and immune responses. In addition to
regulating gene expression, they regulate the protein stability
by dominating the downstream eﬀector responses that are
responsible for the cell fate [69].
Postnatal developments like erythropoiesis, development
of immune system, and other cell signaling cascades are
regulated not only by chromatin methylation/demethylation
but also by targeting speciﬁc amino acid residues for post-
translational modiﬁcation(s) in a given context [64, 65, 71].
The role of methyltransferases in various diseases has
been widely noted. In the case of lysosomal storage dis-
eases, methylation of a speciﬁc lysine of the mitochondrial
ATP synthase plays central role in the accumulation and
storage of this protein in the form of aggregates in the
lysosomalbodies[68].Levelsofhomocysteine,amethylation
product of methionine, plays a major role in cardiovascular
diseases as well as neurological disorders like Parkinson’s
disease [66, 72]. These diseases are exacerbated by the
excessive accumulation of homocysteine due to the lack of
removal or ineﬃc i e n tm e t a b o l i s mo ft h i sc o m p o u n d[ 72].
However, optimal amount of homocysteine is necessary for
the normal functioning of the body, and its metabolism
is extremely sensitive to internal vitamin B levels. [72].
Therapeutic approaches targeting plasma homocysteine are
being proposed to counter the harmful eﬀects of elevated
homocysteine in patients [72]. Inaccurate methylation of
oncoproteins in various cancers is commonly observed in
conjunction with the upregulation of many lysine demethy-
lases [67].
7. Nitration
Protein nitration and carbonylation are the by-products of
the protein oxidation reactions. Nitration is a reversible
and a stable post-translational modiﬁcation that is initiated
when amino acids are exposed to nitrating agents or
oxidative stress [59]. Formation of protein carbonyls and
nitroderivatives is classic hallmark of exposure to genotoxic
stress [73]. Nitroproteins are thought to be involved in a
plethora of diseases. Nitrotyrosine, a chief nitration product,
is associated with many neurodegenerative diseases, lung
diseases, inﬂammation, cardiac diseases, and cancer [74]. In
addition, nitrotyrosine has been implicated in the regulation
of various cell signaling pathways thus activating or inhibit-
ing certain cellular transduction signals depending on the
context of cellular physiology at any given time [75, 76].
A recent study has highlighted that the conversion of a
tyrosine 253 of HDAC2 to nitrotyrosine not only abrogates
its activity in the cell but also targets it for rapid proteasomal
degradation and ultimately aﬀects the gene regulation in the
cell. This study is particularly important for novel cancer
therapies that explore the option of HDAC inhibitors [77].
Furthermore, this study proposes a mechanism explaining
the underlying eﬀect of nitrosative stress in the context of
a neoplastic transformation. It should be noted that certain
ﬂavonoids have been shown to inhibit protein nitration as
well as induce cellular antioxidant defense response [78, 79].
Such phytochemicals seem to have a potential therapeutic
value, especially in cases of cancer and ischemic retinopathy.
At least one mechanistic study has provided strong evidence
in recommending dietary supplements like epicatechin and
N-acetylcysteine (NAC), both of which inhibit tyrosine
nitration, to alleviate diabetic retinopathy and ischemic
retinopathy that result from excessive nitrosative stress [79].
An in vitro mass spectrometric analysis of Lewy bodies
in Parkinson’s disease was able to capture the classical
hallmark of the disease, an increase in 3-nitrotyrosine (3-
NT) modiﬁcation for various proteins [80]. Such elegant
studies not only further our understanding of protein
nitrosylation but also shed light on the intrinsic complexity
of this modiﬁcation that can be useful in designing targeted
therapy for such a debilitating neurological malady [81].
Additionally, 3-NT and nitrated A2E proteins have
recently been proposed as biomarkers for age-related mac-
ular degeneration (AMD) since their accumulation increases
with age and speciﬁcally with increased nitrative stress [82].
3-NT is routinely used as a biomarker for protein damage
that is induced by oxidative inﬂammation [83]. Continual
overproduction of nitric oxide or NO is a classical marker
















































Figure 1: Post-translational modiﬁcations for p53, a tumor-suppressor protein, responsible for maintaining the genomic stability in a cell.
The ﬁgure illustrates various posttranslational modiﬁcations that are frequently observed in p53 with varied functional implications in
normal and/or diseased condition. The amino acid residues that most often undergo the respective modiﬁcations in a given context have
been highlighted. For details of posttranslational alterations in p53 refer to [113–127].
only can damage the organelles but is also a contributing
factor for cell death mainly by mediating apoptosis [84].
Nitrative controlled apoptosis in hepatic stellate cells (HSCs)
is crucial because protein nitration plays a signiﬁcant role in
liver ﬁbrosis prognosis [84].
Peroxynitrite, another harmful nitration product formed
from NO and superoxide ion, along with nitrotyrosine
was shown to contribute to amyloid β-peptide-induced
toxicityandtauproteinneuroﬁbrillarytanglesinAlzheimer’s
patients[85].Peroxynitriteandcellularnitroproteinsarealso
linked with inﬂammation of human colonic epithelium, a
symptom of irritable bowel syndrome (IBS) [86].
8. Palmitoylation
Palmitoylation is a unique reversible cysteine thioaylaction
modiﬁcation that consists of covalent attachment of the
fatty acid, mainly palmitic acid, to the protein molecule
[87, 88]. This modiﬁcation is unique, partly because of its
reversible nature as compared to the other lipid-protein
modiﬁcations like prenylation/isoprenylation and myristoy-
lation, both of which are irreversible and co-translational
reactions. However, these reactions tend to make proteins
more hydrophobic as they add lipid molecule(s) to the
protein structure. These modiﬁcations are also involved
in cell traﬃcking, membrane stimuli, and protein-protein
interactions [87, 88]. Palmitoylation was shown to play
a regulator role in the G-protein linked cell signaling
pathways via modiﬁcation of the regulators of G protein
signaling (RGS) proteins [89]. Palmitoylation of a speciﬁc
cysteine residue in the RGS protein not only regulates the
activity of the protein but also is an important mediator
for localization and targeting of certain G-proteins and
for modulating G-protein signaling [89]. However, in the
case of thyrotropin-releasing hormone (TRH) receptor type
1 (TRH-R1), palmitoylation is not required speciﬁcally
for G-protein signaling but for maintaining the inactive
form of the receptor, since the unpalmitolyated form is
constitutivelyactiveandleadstooversecretionofthyrotropin
and prolactin [90]. Apart from the G-protein traﬃcking,
palmitoylation is closely involved in the neural inﬂammatory
response including demyelinating diseases as well as T-cell
autoimmune responses [91]. Hence, a novel approach using
the stability of palmitoylated proteins to present as antigens
to the MHC-class II immune response is being proposed
in order to beneﬁt the patients with autoimmune diseases
including multiple sclerosis [91].
Reduced or dysfunctional palmitoylation has been linked
to many diseases and disorders [92–96]. In diabetic vascular
disease, eﬃcient palmitoylation of the endothelial nitric
oxide synthase (eNOS) is a required step for eﬃcient
bioavailability of eNOS so it can be targeted to the plasma
membrane [93]. Lack of eNOS palmitoylation, as observed
in insulin-deﬁcient or insulin-resistant patients, leads to the
chronic inﬂammatory response in these patients [93]. Inef-
ﬁcient palmitoylation of the γ-secretase, a component of the
β-amyloid aggregate, in Alzheimer’s disease adversely aﬀects
thepropertraﬃckingandfunctionalpotentialoftheneurons
[92]. Again, lack of the distinct cysteine palmitoylation of the
Huntington protein (HTT), a player in Huntington’s disease,Journal of Amino Acids 7
increases neural toxicity and enhances rapid formation of
inclusion bodies, further deteriorating the patient prognosis
[94].
In some of the disorders, protein palmitoylation can
worsen the disease outcome. Cysteine 172 residue of Hep-
atitis virus C core protein (that forms the viral nucleocapsid)
undergoesanessentialstepofpalmitoylation,inordertoeﬃ-
cientlymultiplythevirionparticlesandthussustainanactive
infection in the host cells [95]. Palmitoylated oncogenic
NRAS is a proposed target for developing therapies against
NRAS-associated malignancies like acute myeloid leukemia
(AML) as well as other types of NRAS-ampliﬁed leukemias
[96]. With such a contradictory role for the palmitoylation,
researchers have developed novel probes that can be utilized
for the ﬂuorescence microscopy and mass spectrometry
analysis of protein palmitoylation [97].
9. Phosphorylation
Phosphorylation,addition ofaphosphategrouptoanamino
acid, is one of the central reversible, post-translational
modiﬁcations that regulate cellular metabolism, protein-
protein interaction, enzyme reactions, and protein degrada-
tion for a myriad of proteins, which results in intracellular
signaling cascades [98, 99]. This reaction is mediated by
a number of protein kinases (PKs) in the cell. Conversely,
dephosphorylation or removal of a phosphate group is an
enzymatic reaction catalyzed by various phosphatases (PPs)
[98]. The ERK1/ERK2-MAPK signaling (mitogen-activated
protein kinase), a central cell proliferation pathway which
interceptswiththereceptortyrosinekinases(RTKs)pathway,
and cell cycle progression proteins like cyclin-dependent
kinases (CDKs) are some of the networks that are aﬀected
bythephosphorylation/dephosphorylationstatusofproteins
[98]. Thus, a proper balance of action between the PKs and
PPs is a key to maintain cellular homeostasis. Autophagy,
a cell death mechanism, is also phosphorylation-dependent
[100]. At least, one report has shown that the autophospho-
rylationeventoftheAtg1proteinisa“regulatoryswitch”that
determines the initiation of the process [100].
Serine/threonine (Ser/Thr) and tyrosine are the most
commonly observed phosphorylated amino acid residues
and have been frequently implicated in progression of
cancers[101–103].Forexample,okadaicacidpresentinshell
ﬁsh poisoning rapidly stimulates Ser/Thr phosphorylation in
an intact cell while simultaneously inhibiting many phos-
phatases thus inducing phosphorylation-mediated signaling
cascades which promote uncontrolled cell proliferation [102,
104]. Dysregulated phosphorylation has been implicated in
neurological diseases like Parkinson’s and dementia that
harbor the accumulation of the Lewy bodies [104]. Ser-
129 phosphorylation of α-synuclein protein is responsible
for the build-up of proteolytic Lewy aggregates [104]. In
case of lung cancer, at least one distinct threonine (T163)
phosphorylation event on the protein Mcl-1, induced by
nicotine (an active ingredient of tobacco), is responsible
for chemoresistance in these tumors [105]. Thus, a single
phosphorylation event in this case is responsible for cell
survival due to blocking of the antiapoptotic function of
the protein Mcl-1 and promoting tumorigenesis. The role
of protein phosphorylation/dephosphorylation in cancers
and their huge impact in disease pathophysiology has been
extensively reviewed multiple times over the years, with a
steady stream of new discoveries of protein phosphoryla-
tion and their eﬀects in disease pathology [106–109]. The
phosphorylation of eNOS, on the other hand, is a key to its
own regulation that is central in many inﬂammatory and
autoimmune diseases [110]. The regulation of the NF-κB
cascade, which controls chemokine and cytokine responses
and inﬂammation, is activated in response to the stimuli via
phosphorylation. ThisabnormalphosphorylationoftheNF-
κB cascade is a classical hallmark of cancers and chronic
immune disorders [111]. Thus, the molecular targeting of
speciﬁc kinases and phosphatases is seen as a promising
strategy in treating cancer as well as other inﬂammatory
diseases [111, 112].
The eﬀects of the process of protein phosphorylation
on cell physiology are enormous. As such, it is beyond the
scope of this paper to cover every aspect of this ubiquitous
m o d i ﬁ c a t i o n .H o w e v e r ,w eh a v em a d ea ne ﬀort to highlight
few important features of phosphorylation itself as well as
combined eﬀects with other PTMs.
10. Sulfation
N-sulfation or O-sulfation, facilitated by the addition of
a sulfate group by oxygen or nitrogen, respectively, is
another post-translational protein modiﬁcation, commonly
observed for membrane as well as secreted proteins [128–
130]. Sulfated proteins have been observed to play a role
inprotein-proteininteractions,G-proteinreceptorsignaling,
chemokine signaling, and immune responses [131, 132].
However, their precise role in cellular regulation still remains
somewhat enigmatic [129]. Gao et al. showed that tyrosine
sulfation was involved in cellular calcium transportation
and mediating association between the chemokine receptor
(CXCR3) and IFN γ-inducible protein-10 (IP-10) [133].
As mentioned above, tyrosine sulfation is a key player
in many diseases including autoimmune response, HIV
infection, lung diseases, multiple sclerosis, and cellular
enzyme regulation [131, 134–137]. Heavy sulfation of high-
molecular weight glycoconjugates (HMGs) produced by cys-
tic ﬁbrosis (CF) respiratory epithelia was shown to adversely
aﬀect the association between HMG and airway secretions
and possibly create a breeding ground for harmful bacteria
like P. aeruginosa and S. aureus in the CF airways and thus
contributing to the pathogenesis of the disease [136]. Other
lung diseases like chronic obstructive pulmonary disease
(COPD) and asthma are equally aggravated due to induction
of chemokine signaling by the tyrosine sulfation and thus
aﬀecting the downstream molecular players along with the
leukocyte traﬃcking and airway inﬂammation [135, 138].
Tyrosine sulfation still remains one of the major post-
translational modiﬁcations that is involved in multiple
disorders [131, 135, 136, 138]. Thus it is also being proposed
as a molecular target for developing a prophylaxis against
HIV1 infection as it greatly diversiﬁes the antigen availability
and presentation beyond the standard 20 amino acids8 Journal of Amino Acids
[134]. Given its role and potential as a target for the drug
development, there are few sulfation site(s) prediction tools,
like that of random forest algorithm, being tested [139].
Techniques like mass spectrometry that are highly sensitive
and speciﬁc for “sulfoproteome” analysis due to the presence
of the sulfoester bond in the sulfated amino acids are
frequently used [129, 140].
11.Ubiquitination
Ubiquitination is a highly dynamic, coordinated, and enzy-
matically catalyzed post-translational modiﬁcation that tar-
gets proteins for degradation and recycling [141]. Proteins
that are targeted for degradation are tagged by a covalent
attachment of a small regulatory protein, ubiquitin (Ub)
[141, 142]. This process is called ubiquitination which is a
multistep enzymatic process [142]. It consists of three main
enzyme classes that act in a speciﬁc order: Ub activating
enzymes (E1), Ub conjugating enzymes (E2), and Ub ligases
(E3) [143]. Proteins targeted for degradation can be mono-
Ub or poly-Ub which is dependent on the type and local-
ization of the substrate. Some of the notable multi-subunit
E3(s) are anaphase-promoting complex (APC) and the SCF
complex(Skp1-Cullin-F-boxproteincomplex)thatgenerally
destine the target protein for the proteasomal degradation.
Another group of proteins called ubiquitin-like proteins
(ULPs), which also follow the traditional path of sequential
E1-E2-E3 processing for undergoing ubiquitination modiﬁ-
c a t i o n ,n e e dam e n t i o n[ 144]. They modify cellular targets
in a pathway that is parallel to Ub but they maintains its
distinctiveness [144]. Three of these ULPs that have received
a lot of attention are NEDD8, Sentrin/SUMO, and Apg12
[144]. Ubiquitination is critical in almost every cellular
p r o c e s sa sw e l la sam a j o rp l a y e ri na l m o s ta n yd i s e a s eo r
disorder. Ubiquitination has a role in modulating diverse
cellular functions like cell proliferation and diﬀerentiation,
autophagy, apoptosis, immune response, DNA repair, neural
degeneration, myogenesis, and stress response [145–147]. It
alsoaﬀectstheoutcomeofmanylife-threateningdiseaseslike
cancer, neurodegenerative disorders, HIV infection, Herpes,
and liver diseases [148–151]. A bi-functional ubiquitin
editing protein called A20 was shown to regulate NF-κB
signaling, aﬀecting gene transcription, cell proliferation, and
inﬂammatory responses [147]. It is also linked with the
inhibiting Beclin-1 ubiquitination, an autophagy inducer
protein, thus limiting the autophagic response [145]. A
transcription factor that regulates the cellular antioxidant
defense, NFE2L2, is stabilized and thus protected from
the Ub-proteasomal degradation via six conserved cysteine
residues on the N-terminal of the NFE2L2 [128]. NFE2L2-
mediated gene regulation has been proposed as a therapeutic
alternative not only in cancer but also for neurodegenerative
diseases that show high oxidative stress like Batten’s and
Parkinson’s diseases [152, 153]. Even though, these studies
propose usage of ubiquitination inhibitors that are eﬀective
in cancer and neurological diseases as they stabilize tumor
suppressor proteins and antioxidant defense mediators, the
process of proteasomal degradation can be equally helpful
in alleviating these diseases [154, 155]. One of the examples
where ubiquitination might be beneﬁcial is the proteasomal
degradation of nuclear as well as oncogenic IκB protein, a
player in the NF-κB signaling [147]. However, there are at
leastafewdrugs,forexample,Bortezomib,anFDAapproved
cancer treatment drug, that are inhibitors of ubiquitination
and commonly used as a part of the treatment regimen for
the cancer and other neural diseases [154].
12. Conclusion
Despite considerable eﬀorts to understand the relevance of
posttranslational modiﬁcations in the cellular context, we
are still in the process of unraveling the complexity of these
modiﬁcations and their tremendous impact. Sophisticated
technological advances like high resolution mass spectrom-
etry and reliable in silico tools are now increasingly available
for identiﬁcation and characterization of these site-speciﬁc
protein alterations. One such novel application is the role
of glycosylation resulting in the formation of disorderly
proteinsorintrinsicallyunstructuredproteins(IUPs).Disor-
derly proteins are newly discovered proteins that are heavily
modiﬁed by the post translational mechanisms resulting in
non-functional or dysfunctional protein molecules. These
proteins have been shown to play an essential role in
gene transcription, protein expression, enzyme activities, cell
signaling cascades, and so forth. Due to their role in disease
pathology and cellular homeostasis, these protein molecules
are actively sought after molecular targets for developing
d r u g sf o rc a n c e rt r e a t m e n ta sw e l la so t h e rc h r o n i cd i s e a s e s .
Other well-known protein modiﬁcations like phosphoryla-
tion are key players in expanding the avenue of translational
medicine for heterogeneous diseases like cancer.
With the constant addition of new post-translational
modiﬁcations, veriﬁcation of newly identiﬁed proteins
changesbytraditionalmethodsandcorrelatingthebiological
signiﬁcance is a challenging task. We are just beginning to
grasp the enormity of the ﬁeld and its eﬀect on the normal
development and disease pathophysiology.
Continued search and evaluation of various functional
modiﬁcations of proteins and understanding their interac-
tion in various biological pathways have important impli-
cations in the successful development of novel prognostic
m a r k e r sa sw e l la st h e r a p e u t i ct a r g e t sf o rc a n c e r ,s e v e r e
neurodegenerative diseases, and other debilitating genetic
disorders.
Conﬂict of Interests
The authors have no conﬂict of interests.
References
[1] X. Li and T. M. Kapoor, “Approach to proﬁle proteins
that recognize post-translationally modiﬁed histone ”tails”,”
Journal of the American Chemical Society, vol. 132, no. 8, pp.
2504–2505, 2010.
[2] N. Sundararajan, D. Mao, S. Chan et al., “Ultrasensitive
detection andcharacterization ofposttranslationalmodiﬁca-
tions using surface-enhanced Raman spectroscopy,” Analyti-
cal Chemistry, vol. 78, no. 11, pp. 3543–3550, 2006.Journal of Amino Acids 9
[3] N. Khidekel and L. C. Hsieh-Wilson, “A ’molecular switch-
board’—covalent modiﬁcations to proteins and their impact
on transcription,” Organic and Biomolecular Chemistry, vol.
2, no. 1, pp. 1–7, 2004.
[4] W. H. McDonald and J. R. Yates, “Shotgun proteomics and
biomarker discovery,” Disease Markers, vol. 18, no. 2, pp. 99–
105, 2002.
[5] C. Wang et al., “Acetylation and nuclear receptor action,” The
Journal of Steroid Biochemistry and Molecular Biology, vol.
123, no. 3–5, pp. 91–100, 2011.
[6] J. K. Choi and L. J. Howe, “Histone acetylation: truth of
consequences?” Biochemistry and Cell Biology, vol. 87, no. 1,
pp. 139–150, 2009.
[7] M. Arif, P. Senapati, J. Shandilya, and T. K. Kundu, “Protein
lysine acetylation in cellular function and its role in cancer
manifestation,” Biochimica et Biophysica Acta, vol. 1799, no.
10–12, pp. 702–716, 2010.
[8] M. A. Glozak, N. Sengupta, X. Zhang, and E. Seto, “Acety-
lation and deacetylation of non-histone proteins,” Gene, vol.
363, no. 1-2, pp. 15–23, 2005.
[9] R. Chammas, J. L. Sonnenburg, N. E. Watson et al.,
“De-N-acetyl-gangliosides in humans: unusual subcellular
distribution of a novel tumor antigen,” Cancer Research, vol.
59, no. 6, pp. 1337–1346, 1999.
[10] M. P. Mattson, “Acetylation unleashes protein demons of
dementia,” Neuron, vol. 67, no. 6, pp. 900–902, 2010.
[11] S. Peleg, F. Sananbenesi, A. Zovoilis et al., “Altered his-
tone acetylation is associated with age-dependent memory
impairment in mice,” Science, vol. 328, no. 5979, pp. 753–
756, 2010.
[ 1 2 ]Z .L u ,I .S c o t t ,B .R .W e b s t e r ,a n dM .N .S a c k ,“ T h ee m e r g -
ing characterization of lysine residue deacetylation on the
modulation of mitochondrial function and cardiovascular
biology,” Circulation Research, vol. 105, no. 9, pp. 830–841,
2009.
[13] A. K. Voss and T. Thomas, “MYST family histone acetyl-
transferases take center stage in stem cells and development,”
BioEssays, vol. 31, no. 10, pp. 1050–1061, 2009.
[14] W. K. Maas, G. D. Novelli, and F. Lipmann, “Acetylation
of glutamic acid by extracts of Escherichia coli,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 39, no. 10, pp. 1004–1008, 1953.
[15] Y.-T. Wu, S.-B. Wu, W.-Y. Lee, and Y.-H. Wei, “Mito-
chondrial respiratory dysfunction-elicited oxidative stress
and posttranslational protein modiﬁcation in mitochondrial
diseases,” Annals of the New York Academy of Sciences, vol.
1201, pp. 147–156, 2010.
[16] K. K. Bhakat, S. K. Mokkapati, I. Boldogh, T. K. Hazra,
and S. Mitra, “Acetylation of human 8-oxoguanine-DNA
glycosylase by p300 and its role in 8-oxoguanine repair in
vivo,”Molecularand CellularBiology, vol.26, no.5,pp.1654–
1665, 2006.
[17] G. Arunachalam, H. Yao, I. K. Sundar, S. Caito, and I. Rah-
man,“SIRT1regulatesoxidant-andcigarettesmoke-induced
eNOS acetylation in endothelial cells: role of resveratrol,”
Biochemical and Biophysical Research Communications, vol.
393, no. 1, pp. 66–72, 2010.
[18] O. M. Sobulo, J. Borrow, R. Tomek et al., “MLL is fused
to CBP, a histone acetyltransferase, in therapy-related acute
myeloid leukemia with a t(11;16)(q23;p13.3),” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 94, no. 16, pp. 8732–8737, 1997.
[19] J. Patel, R. R. Pathak, and S. Mujtaba, “The biology of
lysine acetylation integrates transcriptional programming
and metabolism,” Nutrition and Metabolism, vol. 8, p. 12,
2011.
[20] I. Dalle-Donne, G. Aldini, M. Carini, R. Colombo, R. Rossi,
and A. Milzani, “Protein carbonylation, cellular dysfunction,
and disease progression,” Journal of Cellular and Molecular
Medicine, vol. 10, no. 2, pp. 389–406, 2006.
[21] C. M. Wong, L. Marcocci, L. Liu, and Y. J. Suzuki, “Cell
signaling by protein carbonylation and decarbonylation,”
Antioxidants and Redox Signaling, vol. 12, no. 3, pp. 393–404,
2010.
[22] G. Wang, J. Wang, H. Ma, and M. F. Khan, “Increased nitra-
tion and carbonylation of proteins in MRL+/+ mice exposed
to trichloroethene: potential role of protein oxidation in
autoimmunity,” Toxicology and Applied Pharmacology, vol.
237, no. 2, pp. 188–195, 2009.
[ 2 3 ]K .R .A t k u r i ,T .M .C o w a n ,T .K w a ne ta l . ,“ I n h e r i t e dd i s -
orders aﬀecting mitochondrial function are associated with
glutathione deﬁciency and hypocitrullinemia,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 106, no. 10, pp. 3941–3945, 2009.
[24] T. Nystr¨ om, “Role of oxidative carbonylation in protein
quality control and senescence,” EMBO Journal, vol. 24, no.
7, pp. 1311–1317, 2005.
[25] A. G. Madian and F. E. Regnier, “Proteomic identiﬁcation of
carbonylated proteins and their oxidation sites,” Journal of
Proteome Research, vol. 9, no. 8, pp. 3766–3780, 2010.
[ 2 6 ]B .W .N e w t o n ,W .K .R u s s e l l ,D .H .R u s s e l l ,S .K .R a m a i a h ,
and A. Jayaraman, “Liver proteome analysis in a rodent
model of alcoholic steatosis,” J o u r n a lo fP r o t e o m eR e s e a r c h ,
vol. 8, no. 4, pp. 1663–1671, 2009.
[27] E. Barreiro, D. S´ anches, J. B. G´ aldiz, S. N. A. Hussain, and
J. Gea, “N-acetylcysteine increases manganese superoxide
dismutase activity in septic rat diaphragms,” European Res-
piratory Journal, vol. 26, no. 6, pp. 1032–1039, 2005.
[28] T. Kabuta, R. Setsuie, T. Mitsui et al., “Aberrant molecular
properties shared by familial Parkinson’s disease-associated
mutant UCH-L1 and carbonyl-modiﬁed UCH-L1,” Human
Molecular Genetics, vol. 17, no. 10, pp. 1482–1496, 2008.
[29] J. Choi, M. C. Sullards, J. A. Olzmann et al., “Oxidative dam-
age of DJ-1 is linked to sporadic Parkinson and Alzheimer
diseases,” Journal of Biological Chemistry, vol. 281, no. 16, pp.
10816–10824, 2006.
[30] A. G. Madian and F. E. Regnier, “Proteomic identiﬁcation of
carbonylated proteins and their oxidation sites,” Journal of
Proteome Research, vol. 9, no. 8, pp. 3766–3780, 2010.
[31] A. Varki and N. Sharon, “Historical background and
overview,” in Essentials of Glycobiology, Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, NY, USA, 2009.
[32] A. Varki and J. B. Lowe, Biological Roles of Glycans, 2009.
[33] J. F. Rakus and L. K. Mahal, “New technologies for glycomic
analysis: toward a systematic understanding of the glycome,”
Annual Review of Analytical Chemistry, vol. 4, no. 1, pp. 367–
392, 2011.
[34] J. Xue, Q. Zhao, L. Zhu, and W. Zhang, “Deglycosylation of
FcαR at N58 increases its binding to IgA,” Glycobiology, vol.
20, no. 7, pp. 905–915, 2010.
[35] J. D. M´ endez, J. Xie, M. Aguilar-Hern´ andez, and V. M´ endez-
Valenzuela, “Trends in advanced glycation end products
research in diabetes mellitus and its complications,” Molec-
ular and Cellular Biochemistry, vol. 341, no. 1-2, pp. 33–41,
2010.10 Journal of Amino Acids
[36] T. G. Szab´ a, R. Palotai, P. Antal et al., “Critical role of
glycosylation in determining the length and structure of T
cell epitopes,” Immunome Research, vol. 5, no. 1, Article ID 4,
2009.
[37] M. Broncel, J. A. Falenski, S. C. Wagner, C. P. R. Hack-
enberger, and B. Koksch, “How post-translational modi-
ﬁcations inﬂuence amyloid formation: a systematic study
of phosphorylation and glycosylation in model peptides,”
Chemistry, vol. 16, no. 26, pp. 7881–7888, 2010.
[38] M. K. Salamat, M. Dron, J. Chapuis, C. Langevin, and H.
Laude, “Prion propagation in cells expressing PrP glycosy-
lation mutants,” Journal of Virology, vol. 85, no. 7, pp. 3077–
3085, 2011.
[39] Y. Lee, M. Kockx, M. J. Raftery, W. Jessup, R. Griﬃth, and
L.Kritharides,“Glycosylationandsialylationofmacrophage-
derived human apolipoprotein E analyzed by SDS-PAGE and
mass spectrometry: evidence for a novel site of glycosylation
on SER290,” Molecular and Cellular Proteomics, vol. 9, no. 9,
pp. 1968–1981, 2010.
[40] H. J. F. MacCioni, R. Quiroga, and M. L. Ferrari, “Cellular
and molecular biology of glycosphingolipid glycosylation,”
Journal of Neurochemistry, vol. 117, no. 4, pp. 589–602, 2011.
[41] J. D. M´ endez, J. Xie, M. Aguilar-Hern´ andez, and V. M´ endez-
Valenzuela, “Molecular susceptibility to glycation and its
implication in diabetes mellitus and related diseases,” Molec-
ular and Cellular Biochemistry, vol. 344, no. 1-2, pp. 185–193,
2010.
[42] R. H. Nagaraj, M. Linetsky, and A. W. Stitt, “The pathogenic
roleofMaillardreactionintheagingeye,” Amino Acids,2010.
In press.
[43] N. Ahmed, “Advanced glycation endproducts—role in
pathology of diabetic complications,” Diabetes Research and
Clinical Practice, vol. 67, no. 1, pp. 3–21, 2005.
[44] B. C. Creagh-Brown, G. J. Quinlan, T. W. Evans, and A.
Burke-Gaﬀney, “The RAGE axis in systemic inﬂammation,
acute lung injury and myocardial dysfunction: an important
therapeutic target?” Intensive Care Medicine, vol. 36, no. 10,
pp. 1644–1656, 2010.
[ 4 5 ]D .S .A l o n z ia n dT .D .B u t t e r s ,“ T h e r a p e u t i ct a r g e t sf o r
inhibitors of glycosylation,” Chimia, vol. 65, no. 1-2, pp. 35–
39, 2011.
[ 4 6 ]R .A .D w e k ,T .D .B u t t e r s ,F .M .P l a t t ,a n dN .Z i t z m a n n ,
“Targeting glycosylation as a therapeutic approach,” Nature
Reviews Drug Discovery, vol. 1, no. 1, pp. 65–75, 2002.
[47] P. K. Sengupta, M. P. Bouchie, and M. A. Kukuruzinska, “N-
glycosylation gene DPAGT1 is a target of the Wnt/β-catenin
signaling pathway,” Journal of Biological Chemistry, vol. 285,
no. 41, pp. 31164–31173, 2010.
[48] D. J. Prockop and K. Juva, “Synthesis of hydroxyproline
in vitro by the hydroxylation of proline in a precursor of
collagen,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 53, pp. 661–668, 1965.
[49] C. I. Levene, C. D. Ockleford, and C. L. Barber, “Scurvy:
a comparison between ultrastructural and biochemical
changes observed in cultured ﬁbroblasts and the collagen
they synthesise,” Virchows Archiv Abteilung B Cell Pathology,
vol. 23, no. 4, pp. 325–338, 1977.
[50] K. I. Kivirikko, R. Myllyl¨ a, and T. Pihlajaniemi, “Protein
hydroxylation: prolyl 4-hydroxylase, an enzyme with four
cosubstrates and a multifunctional subunit,” The FASEB
Journal, vol. 3, no. 5, pp. 1609–1617, 1989.
[51] D.D.VanSlykeandF.M.Sinex,“Thecourseofhydroxylation
of lysine to form hydroxylysine in collagen,” The Journal of
Biological Chemistry, vol. 232, no. 2, pp. 797–806, 1958.
[52] P. Jaakkola, D. R. Mole, Y. M. Tian et al., “Targeting of HIF-
α to the von Hippel-Lindau ubiquitylation complex by O2-
r e g u l a t e dp r o l y lh y d r o x y l a t i o n , ”Science, vol. 292, no. 5516,
pp. 468–472, 2001.
[53] D. Lando, D. J. Peet, D. A. Whelan, J. J. Gorman, and
M. L. Whitelaw, “Asparagine hydroxylation of the HIF
transactivation domain: a hypoxic switch,” Science, vol. 295,
no. 5556, pp. 858–861, 2002.
[54] A. Siddiq, L. R. Aminova, and R. R. Ratan, “Hypoxia
inducible factor prolyl 4-hydroxylase enzymes: center stage
in the battle against hypoxia, metabolic compromise and
oxidative stress,” Neurochemical Research, vol. 32, no. 4-5, pp.
931–946, 2007.
[55] D. A. Chan, P. D. Sutphin, N. C. Denko, and A. J. Giaccia,
“Role of prolyl hydroxylation in oncogenically stabilized
hypoxia-inducible factor-1α,” JournalofBiologicalChemistry,
vol. 277, no. 42, pp. 40112–40117, 2002.
[56] J. Myllyharju, “HIF prolyl 4-hydroxylases and their potential
as drug targets,” Current Pharmaceutical Design, vol. 15, no.
33, pp. 3878–3885, 2009.
[57] L.-L. Hu, S. Niu, T. Huang, K. Wang, X.-H. Shi, and Y.-D.
Cai, “Prediction and analysis of protein hydroxyproline and
hydroxylysine,” PLoS One, vol. 5, no. 12, p. e15917, 2010.
[58] P. F. Fitzpatrick, “Mechanism of aromatic amino acid
hydroxylation,” Biochemistry, vol. 42, no. 48, pp. 14083–
14091, 2003.
[ 5 9 ]N .B l a u ,F .J .v a nS p r o n s e n ,a n dH .L .L e v y ,“ P h e n y l k e -
tonuria,” Lancet, vol. 376, no. 9750, pp. 1417–1427, 2010.
[60] H. Hedstrand, O. Ekwall, J. Haavik et al., “Identiﬁcation
of tyrosine hydroxylase as an autoantigen in autoimmune
polyendocrine syndrome type I,” Biochemical and Biophysical
Research Communications, vol. 267, no. 1, pp. 456–461, 2000.
[61] M. Ohno, M. Okamoto, N. Kawabe et al., “Oudenone, a
novel tyrosine hydroxylase inhibitor from microbial origin,”
Journal of the American Chemical Society,v o l .9 3 ,n o .5 ,p p .
1285–1286, 1971.
[62] S. Ayukawa, T. Takeuchi, M. Sezaki, T. Hara, and
H. Umezawa, “Inhibition of tyrosine hydroxylase by




hydroxylase and its implications for the biosynthesis of the
neurotransmitters serotonin and melatonin,” Biochemistry,
vol. 41, no. 42, pp. 12569–12574, 2002.
[64] M. R. W. Mann and M. S. Bartolomei, “Epigenetic repro-
gramminginthemammalianembryo:struggleoftheclones,”
Genome Biology, vol. 3, no. 2, pp. 1–4, 2002.
[65] I. C. G. Weaver, “Epigenetic programming by maternal
behavior and pharmacological intervention—nature versus
nurture: let’s call the whole thing oﬀ,” Epigenetics, vol. 2, no.
1, pp. 22–28, 2007.
[ 6 6 ]N .P .B .D u d m a n ,X . - W .G u o ,R .B .G o r d o n ,P .A .D a w s o n ,
and D. E. L. Wilcken, “Human homocysteine catabolism:
three major pathways and their relevance to development of
arterial occlusive disease,” Journal of Nutrition, vol. 126, no.
4, supplement, pp. 1295S–1300S, 1996.
[67] J. M. Wagner, B. Hackanson, M. L¨ ubbert, and M. Jung,
“Histone deacetylase (HDAC) inhibitors in recent clinical
trials for cancer therapy,” Clinical Epigenetics, vol. 1, no. 3-4,
pp. 117–136, 2010.Journal of Amino Acids 11
[68] M. L. Katz and M. Rodrigues, “Juvenile ceroid lipofuscinosis.
Evidence for methylated lysine in neural storage body
protein,” American Journal of Pathology, vol. 138, no. 2, pp.
323–332, 1991.
[69] X. D. Yang, A. Lamb, and L. F. Chen, “Methylation, a new
epigenetic mark for protein stability,” Epigenetics, vol. 4, no.
7, pp. 429–433, 2009.
[70] E. M. Duncan and C. D. Allis, “Errors in erasure: links
between histone lysine methylation removal and disease,”
Progress in Drug Research, vol. 67, pp. 69–90, 2011.
[71] M. D. Litt, M. Simpson, M. Gaszner, C. D. Allis, and G.
Felsenfeld, “Correlation between histone lysine methylation
and developmental changes at the chicken β-globin locus,”
Science, vol. 293, no. 5539, pp. 2453–2455, 2001.
[72] J. T. Brosnan, R. L. Jacobs, L. M. Stead, and M. E. Brosnan,
“Methylation demand: a key determinant of homocysteine
metabolism,” Acta Biochimica Polonica, vol. 51, no. 2, pp.
405–413, 2004.
[73] H. Ischiropoulos, “Protein tyrosine nitration—an update,”
Archives of Biochemistry and Biophysics, vol. 484, no. 2, pp.
117–121, 2009.
[ 7 4 ]N .A b e l l o ,H .A .M .K e r s t j e n s ,D .S .P o s t m a ,a n dR .B i s c h o ﬀ,
“Protein tyrosine nitration: selectivity, physicochemical and
biological consequences, denitration, and proteomics meth-
ods for the identiﬁcation of tyrosine-nitrated proteins,”
Journal of Proteome Research, vol. 8, no. 7, pp. 3222–3238,
2009.
[75] V. A. Yakovlev and R. B. Mikkelsen, “Protein tyrosine
nitration in cellular signal transduction pathways,” Journal of
ReceptorsandSignalTransduction,vol.30,no.6,pp.420–429,
2010.
[76] Y. B. Blume, Y. A. Krasylenko, and A. I. Yemets, “Tyrosine
nitration as regulatory posttranslational modiﬁcation of
proteins,” Ukrainskii Biokhimicheskii Zhurnal,v o l .8 1 ,n o .5 ,
pp. 5–15, 2009.
[77] G. O. Osoata, S. Yamamura, M. Ito et al., “Nitration of
distinct tyrosine residues causes inactivation of histone
deacetylase 2,” Biochemical and Biophysical Research Commu-
nications, vol. 384, no. 3, pp. 366–371, 2009.
[78] N. Wang, D. Li, N. H. Lu, L. Yi, X. W. Huang, and Z. H. Gao,
“Peroxynitrite and hemoglobin-mediated nitrative/oxidative
modiﬁcation of human plasma protein: eﬀects of some
ﬂavonoids,” J o u r n a lo fA s i a nN a t u r a lP r o d u c t sR e s e a r c h , vol.
12, no. 4, pp. 257–264, 2010.
[ 7 9 ]M .A .A b d e l s a i d ,B .A .P i l l a i ,S .M a t r a g o o n ,R .P r a k a s h ,M .
Al-Shabrawey, and A. B. El-Remessy, “Early intervention of
tyrosine nitration prevents vaso-obliteration and neovascu-
larization in ischemic retinopathy,” Journal of Pharmacology
and Experimental Therapeutics, vol. 332, no. 1, pp. 125–134,
2010.
[80] S.R.Danielson,J.M.Held,B.Schilling,M.Oo,B.W.Gibson,
and J. K. Andersen, “Preferentially increased nitration of
α-synuclein at tyrosine-39 in a cellular oxidative model of
Parkinson’s disease,” Analytical Chemistry, vol. 81, no. 18, pp.
7823–7828, 2009.
[81] K. K. K. Chung, “Modulation of pro-survival proteins by S-
nitrosylation: implications for neurodegeneration,” Apopto-
sis, vol. 15, no. 11, pp. 1364–1370, 2010.
[82] L. S. Murdaugh, Z. Wang, L. V. Del Priore, J. Dillon, and E. R.
Gaillard, “Age-related accumulation of 3-nitrotyrosine and
nitro-A2E in human Bruch’s membrane,” Experimental Eye
Research, vol. 90, no. 5, pp. 564–571, 2010.
[83] J. M. Souza, G. Peluﬀo, and R. Radi, “Protein tyrosine
nitration—functional alteration or just a biomarker?” Free
Radical Biology and Medicine, vol. 45, no. 4, pp. 357–366,
2008.
[84] T. Mdol, C. Natal, M. P. P´ erez De Obanos, E. Domingo De
Miguel,M.J .Iraburu,andM.J .L´ opez-Zabalza,“Apoptosisof
hepatic stellate cells mediated by speciﬁc protein nitration,”
Biochemical Pharmacology, vol. 81, no. 3, pp. 451–458, 2011.
[85] F. X. Guix, G. Ill-Raga, R. Bravo et al., “Amyloid-dependent
triosephosphate isomerase nitrotyrosination induces glyca-
tion and tau ﬁbrillation,” Brain, vol. 132, no. 5, pp. 1335–
1345, 2009.
[ 8 6 ]I .I .S i n g e r ,D .W .K a w k a ,S .S c o t te ta l . ,“ E x p r e s s i o no f
inducible nitric oxide synthase and nitrotyrosine in colonic
epitheliumininﬂammatoryboweldisease,”Gastroenterology,
vol. 111, no. 4, pp. 871–885, 1996.
[87] D. I. Mundy, “Protein palmitoylation in membrane traﬃck-
ing,” Biochemical Society Transactions, vol. 23, no. 3, pp. 572–
576, 1995.
[88] C. Salaun, J. Greaves, and L. H. Chamberlain, “The intra-
cellular dynamic of protein palmitoylation,” Journal of Cell
Biology, vol. 191, no. 7, pp. 1229–1238, 2010.
[89] K. M. Druey, O. Ugur, J. M. Caron, C. K. Chen, P. S.
Backlund, and T. L. Z. Jones, “Amino-terminal cysteine
residues of RGS16 are required for palmitoylation and
modulationofG(i)-andG(q)-mediatedsignaling,”Journalof
BiologicalChemistry,vol.274,no.26,pp.18836–18842,1999.
[90] D. Du, B. M. Raaka, H. Grimberg, M. Lupu-Meiri, Y. Oron,
and M. C. Gershengorn, “Carboxyl tail cysteine mutants of
the thyrotropin-releasing hormone receptor type 1 exhibit
constitutive signaling: role of palmitoylation,” Molecular
Pharmacology, vol. 68, no. 1, pp. 204–209, 2005.
[91] N. A. Pfender, S. Grosch, G. Roussel, M. Koch, E. Triﬁlieﬀ,
and J. M. Greer, “Route of uptake of palmitoylated encephal-
itogenic peptides of myelin proteolipid protein by antigen-
presenting cells: importance of the type of bond between
lipid chain and peptide and relevance to autoimmunity,”
Journal of Immunology, vol. 180, no. 3, pp. 1398–1404, 2008.
[92] X. Meckler, J. Roseman, P. Das et al., “Reduced Alzheimer’s
disease β-amyloid deposition in transgenic mice expressing
S-palmitoylation-deﬁcient APH1aL and nicastrin,” Journal of
Neuroscience, vol. 30, no. 48, pp. 16160–16169, 2010.
[93] X. Wei, J. G. Schneider, S. M. Shenouda et al., “De
Novo lipogenesis maintains vascular homeostasis through
endothelial nitric-oxide synthase (eNOS) palmitoylation,”
Journal of Biological Chemistry, vol. 286, no. 4, pp. 2933–
2945, 2011.
[94] A. Yanai, K. Huang, R. Kang et al., “Palmitoylation of hunt-
ingtin by HIP14is essential for its traﬃcking and function,”
Nature Neuroscience, vol. 9, no. 6, pp. 824–831, 2006.
[95] N.M ajeau,R.F r ometin,C.Sa var d,M.Du val,M.J .T r e mbla y ,
and D. Leclerc, “Palmitoylation of hepatitis C virus core
protein is important for virion production,” Journal of
BiologicalChemistry,vol.284,no.49,pp.33915–33925,2009.
[96] B. Cuiﬀo and R. Ren, “Palmitoylation of oncogenic NRAS
is essential for leukemogenesis,” Blood, vol. 115, no. 17, pp.
3598–3605, 2010.
[97] L. Li, L. Dong, L. Xia, T. Li, and H. Zhong, “Chemical and
geneticprobesforanalysisofproteinpalmitoylation,”Journal
of Chromatography B, vol. 879, no. 17-18, pp. 1316–1324,
2011.
[98] T. Hunter, “Protein kinases and phosphatases: the yin and
yang of protein phosphorylation and signaling,” Cell, vol. 80,
no. 2, pp. 225–236, 1995.12 Journal of Amino Acids
[99] G. Ghosh and J. A. Adams, “Phosphorylation mechanism
and structure of serine-arginine protein kinases,” FEBS
Journal, vol. 278, no. 4, pp. 587–597, 2011.
[100] Y.-Y. Yeh, K. Wrasman, and P. K. Herman, “Autophospho-
rylation within the Atg1 activation loop is required for
both kinase activity and the induction of autophagy in
Saccharomyces cerevisiae,” Genetics, vol. 185, no. 3, pp. 871–
882, 2010.
[101] A. J. Levine and A. M. Puzio-Kuter, “The control of
the metabolic switch in cancers by oncogenes and tumor
suppressor genes,” Science, vol. 330, no. 6009, pp. 1340–1344,
2010.
[102] T. A. J. Haystead, A. T. R. Sim, D. Carling et al., “Eﬀects of
the tumour promoter okadaic acid on intracellular protein
phosphorylation and metabolism,” Nature, vol. 337, no.
6202, pp. 78–81, 1989.
[103] T. Patschinsky, T. Hunter, and F. S. Esch, “Analysis of
the sequence of amino acids surrounding sites of tyrosine
phosphorylation,” Proceedings of the National Academy of
SciencesoftheUnitedStatesofAmerica,vol.79,no.4,pp.973–
977, 1982.
[104] J. P. Anderson, D. E. Walker, J. M. Goldstein et al.,
“Phosphorylation of Ser-129 is the dominant pathological
modiﬁcation of α-synuclein in familial and sporadic lewy
body disease,” Journal of Biological Chemistry, vol. 281, no.
40, pp. 29739–29752, 2006.
[105] J. Zhao, M. Xin, T. Wang, Y. Zhang, and X. Deng, “Nicotine
enhances the antiapoptotic function of mcl-1 through phos-
phorylation,” Molecular Cancer Research, vol. 7, no. 12, pp.
1954–1961, 2009.
[106] L. F. Hernandez-Aya and A. M. Gonzalez-Angulo, “Targeting
thephosphatidylinositol3-kinasesignalingpathwayinbreast
cancer,” Oncologist, vol. 16, no. 4, pp. 404–414, 2011.
[107] N. J. MacLaine and T. R. Hupp, “How phosphorylation
controls p53,” Cell Cycle, vol. 10, no. 6, pp. 916–921, 2011.
[108] S. G. Julien, N. Dub´ e, S. Hardy, and M. L. Tremblay, “Inside
the human cancer tyrosine phosphatome,” Nature Reviews
Cancer, vol. 11, no. 1, pp. 35–49, 2011.
[109] H.C.HarshaandA.Pandey,“Phosphoproteomicsincancer,”
Molecular Oncology, vol. 4, no. 6, pp. 482–495, 2010.
[110] G. K. Kolluru, J. H. Siamwala, and S. Chatterjee, “eNOS
phosphorylation in health and disease,” Biochimie, vol. 92,
no. 9, pp. 1186–1198, 2010.
[111] F. Yoboua, A. Martel, A. Duval, E. Mukawera, and N.
Grandvaux, “Respiratory syncytial virus-mediated NF-κB
p65 phosphorylation at serine 536 is dependent on RIG-I,
TRAF6, and IKKβ,” Journal of Virology, vol. 84, no. 14, pp.
7267–7277, 2010.
[112] E. A. Slee, B. Benassi, R. Goldin et al., “Phosphorylation of
Ser312 contributes to tumor suppression by p53 in vivo,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 107, no. 45, pp. 19479–19484, 2010.
[113] A.Cheema,C.D.Knights,M.Raoetal.,“Functionalmimicry
of the acetylated C-terminal tail of p53 by a SUMO-1
acetylated domain, SAD,” Journal of Cellular Physiology, vol.
225, no. 2, pp. 371–384, 2010.
[114] S. Tornaletti and G. P. Pfeifer, “Complete and tissue-
independent methylation of CpG sites in the p53 gene:
implicationsformutationsinhumancancers,”Oncogene,vol.
10, no. 8, pp. 1493–1499, 1995.
[115] A. Deﬃe, H. Wu, V. Reinke, and G. Lozano, “The tumor
suppressor p53 regulates its own transcription,” Molecular
and Cellular Biology, vol. 13, no. 6, pp. 3415–3423, 1993.
[116] R. Wolkowicz and V. Rotter, “The DNA binding regulatory
domain of p53: see the C,” Pathologie Biologie, vol. 45, no. 10,
pp. 785–796, 1997.
[117] F. Fiordaliso, A. Leri, D. Cesselli et al., “Hyperglycemia
activates p53andp53-regulated genesleadingtomyocytecell
death,” Diabetes, vol. 50, no. 10, pp. 2363–2375, 2001.
[118] K. A. Field, D. Holowka, and B. Baird, “FcεRI-mediated
recruitment of p53/56(lyn) to detergent-resistant membrane
domains accompanies cellular signaling,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 92, no. 20, pp. 9201–9205, 1995.
[119] W. Zhang, R. P. Trible, and L. E. Samelson, “LAT palmitoyla-
tion: its essential role in membrane microdomain targeting
and tyrosine phosphorylation during T cell activation,”
Immunity, vol. 9, no. 2, pp. 239–246, 1998.
[120] C.-H. Tang and E. A. Grimm, “Depletion of endogenous
nitric oxide enhances cisplatin-induced apoptosis in a p53-
dependent manner in melanoma cell lines,” Journal of
Biological Chemistry, vol. 279, no. 1, pp. 288–298, 2004.
[121] C. S. Cobbs, T. R. Whisenhunt, D. R. Wesemann, L. E.
Harkins, E. G. Van Meir, and M. Samanta, “Inactivation
of wild-type p53 protein function by reactive oxygen and
nitrogen species in malignant glioma cells,” Cancer Research,
vol. 63, no. 24, pp. 8670–8673, 2003.
[122] D. W. Meek and W. Eckhart, “Phosphorylation of p53 in
normal and simian virus 40-transformed NIH 3T3 cells,”
Molecular and Cellular Biology, vol. 8, no. 1, pp. 461–465,
1988.
[123] D. W. Meek, S. Simon, U. Kikkawa, and W. Eckhart, “The
p53 tumour suppressor protein is phosphorylated at serine
389 by casein kinase II,” EMBO Journal, vol. 9, no. 10, pp.
3253–3260, 1990.
[124] A. Sundqvist, G. Liu, A. Mirsaliotis, and D. P. Xirodimas,
“Regulation of nucleolar signalling to p53 through NEDDy-
lation of L11,” EMBO Reports, vol. 10, no. 10, pp. 1132–1139,
2009.
[125] M. Hollstein and P. Hainaut, “Massively regulated genes: the
example of TP53,” Journal of Pathology, vol. 220, no. 2, pp.
164–173, 2010.
[126] S. Carter and K. H. Vousden, “p53-Ubl fusions as models
of ubiquitination, sumoylation and neddylation of p53,” Cell
Cycle, vol. 7, no. 16, pp. 2519–2528, 2008.
[127] U. P. Steinbrecher, M. Fisher, J. L. Witztum, and L. K. Curtiss,
“Immunogenicity of homologous low density lipoprotein
after methylation, ethylation, acetylation, or carbamylation:
generation of antibodies speciﬁc for derivatized lysine,”
JournalofLipidResearch,vol.25,no.10,pp.1109–1116,1984.
[128] K. L. Moore, “The biology and enzymology of protein
tyrosine O-sulfation,” Journal of Biological Chemistry, vol.
278, no. 27, pp. 24243–24246, 2003.
[129] C. Seibert and T. P. Sakmar, “Toward a framework for sulfo-
proteomics: synthesis and characterization of sulfotyrosine-
containingpeptides,”Biopolymers,vol.90,no.3,pp.459–477,
2008.
[130] M. J. Stone, S. Chuang, X. Hou, M. Shoham, and J. Z.
Zhu, “Tyrosine sulfation: an increasingly recognised post-
translationalmodiﬁcationofsecretedproteins,”NewBiotech-
nology, vol. 25, no. 5, pp. 299–317, 2009.
[131] J. W. Kehoe and C. R. Bertozzi, “Tyrosine sulfation: a modu-
latorofextracellularprotein-proteininteractions,” Chemistry
and Biology, vol. 7, no. 3, pp. R57–R61, 2000.Journal of Amino Acids 13
[132] Y. B. Ouyang, W. S. Lane, and K. L. Moore, “Tyrosylprotein
sulfotransferase: puriﬁcation and molecular cloning of an
enzyme that catalyzes tyrosine O-sulfation, a common
posttranslational modiﬁcation of eukaryotic proteins,” Pro-
ceedings of the National Academy of Sciences of the United
States of America, vol. 95, no. 6, pp. 2896–2901, 1998.
[133] J. M. Gao, R. L. Xiang, L. Jiang et al., “Sulfated tyrosines 27
and 29 in the N-terminus of human CXCR3 participate in
bindingnativeIP-10,”ActaPharmacologicaSinica,vol.30,no.
2, pp. 193–201, 2009.
[134] C. C. Huang, M. Venturi, S. Majeed et al., “Structural basis
of tyrosine sulfation and V-gene usage in antibodies that
recognize the HIV type 1 coreceptor-binding site on gp120,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 101, no. 9, pp. 2706–2711, 2004.
[135] J. Liu, S. Louie, W. Hsu, K. M. Yu, H. B. Nicholas, and
G. L. Rosenquist, “Tyrosine sulfation is prevalent in human
chemokine receptors important in lung disease,” American
Journal of Respiratory Cell and Molecular Biology, vol. 38, no.
6, pp. 738–743, 2008.
[136] P. W. Cheng, T. F. Boat, K. Cranﬁll, J. R. Yankaskas, and R. C.
Boucher, “Increased sulfation of glycoconjugates by cultured
nasal epithelial cells from patients with cystic ﬁbrosis,”
Journal of Clinical Investigation, vol. 84, no. 1, pp. 68–72,
1989.
[137] W. Hsu, G. L. Rosenquist, A. A. Ansari, and M. E. Gersh-
win, “Autoimmunity and tyrosine sulfation,” Autoimmunity
Reviews, vol. 4, no. 7, pp. 429–435, 2005.
[138] A. Rossi, J. Bonaventure, A. L. Delezoide, A. Superti-Furga,
and G. Cetta, “Undersulfation of cartilage proteoglycans ex
vivo and increased contribution of amino acid sulfur to
sulfation in vitro in McAlister dysplasia/atelosteogenesis type
2,” European Journal of Biochemistry, vol. 248, no. 3, pp. 741–
747, 1997.
[139] Z. R. Yang, “Predicting sulfotyrosine sites using the random
forest algorithm with signiﬁcantly improved prediction
accuracy,” BMC Bioinformatics, vol. 10, Article ID 1471, p.
361, 2009.
[140] C. H. Jen and J. A. Leary, “A competitive binding study of
chemokine, sulfated receptor, and glycosaminoglycan inter-
actions by nano-electrospray ionization mass spectrometry,”
Analytical Biochemistry, vol. 407, no. 1, pp. 134–140, 2010.
[141] K. D. Wilkinson, “Protein ubiquitination: a regulatory post-
translational modiﬁcation,” Anti-Cancer Drug Design, vol. 2,
no. 2, pp. 211–229, 1987.
[142] M. Rechsteiner, “Ubiquitin-mediated pathways for intracel-
lular proteolysis,” Annual Review of Cell Biology, vol. 3, pp.
1–30, 1987.
[143] C. M. Pickart, “Targeting of substrates to the 26S protea-
some,” FASEB Journal, vol. 11, no. 13, pp. 1055–1066, 1997.
[144] E. T. H. Yeh, L. Gong, and T. Kamitani, “Ubiquitin-like
proteins: new wines in new bottles,” Gene, vol. 248, no. 1-2,
pp. 1–14, 2000.
[145] C. S. Shi and J. H. Kehrl, “TRAF6 and A20 regulate lysine 63-
linked ubiquitination of Beclin-1 to control TLR4-induced
Autophagy,” Science Signaling, vol. 3, no. 123, p. ra42, 2010.
[146] X. Jin, H. Cheng, J. Chen, and D. Zhu, “RNF13: an emerging
RING ﬁnger ubiquitin ligase important in cell proliferation,”
FEBS Journal, vol. 278, no. 1, pp. 78–84, 2011.
[147] I. Bosanac, I. E. Wertz, B. Pan et al., “Ubiquitin binding
to A20 ZnF4 is required for modulation of NF-kappaB
signaling,” Molecular Cell, vol. 40, no. 4, pp. 548–557, 2010.
[148] A. Keutgens, X. Zhang, K. Shostak et al., “BCL-3 degra-
dation involves its polyubiquitination through a FBW7-
independent pathway and its binding to the proteasome
subunitPSMB1,”JournalofBiologicalChemistry,vol.285,no.
33, pp. 25831–25840, 2010.
[149] P. C. Weber, S. J. Spatz, and E. C. Nordby, “Stable ubiqui-
tination of the ICP0R protein of herpes simplex virus type
1 during productive infection,” Virology, vol. 253, no. 2, pp.
288–298, 1999.
[150] J. R. C. Bergeron, H. Huthoﬀ,D .A .V e s e l k o ve ta l . ,“ T h e
SOCS-boxofHIV-1vifinteractswithelonginBCbyinduced-
folding to recruit its Cul5-containing ubiquitin ligase com-
plex,” PLoS Pathogens, vol. 6, no. 6, p. e1000925, 2010.
[151] C. A. Gutekunst, S. H. Li, H. Yi et al., “Nuclear and
neuropil aggregates in Huntington’s disease: relationship to
neuropathology,” Journal of Neuroscience,v o l .1 9 ,n o .7 ,p p .
2522–2534, 1999.
[152] X. He and Q. Ma, “NRF2 cysteine residues are critical
for oxidant/electrophile-sensing, Kelch-like ECH-associated
protein-1-dependent ubiquitination-proteasomal degrada-
tion, and transcription activation,” Molecular Pharmacology,
vol. 76, no. 6, pp. 1265–1278, 2009.
[153] J. M. Lee and J. A. Johnson, “An important role of Nrf2-
ARE pathway in the cellular defense mechanism,” Journal of
Biochemistry and Molecular Biology, vol. 37, no. 2, pp. 139–
143, 2004.
[154] F. Colland, “The therapeutic potential of deubiquitinating
enzyme inhibitors,” Biochemical Society Transactions, vol. 38,
no. 1, pp. 137–143, 2010.
[155] L. Bedford et al., “Ubiquitin-like protein conjugation and
the ubiquitin-proteasome system as drug targets,” Nature
Reviews Drug Discovery, vol. 10, no. 1, pp. 29–46, 2011.